Metraipolis › archive › dc_8188accc968d

Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial — Europe PMC PMID:41572426

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41572426
DOI
10.1093/oncolo/oyaf432
License (as archived)
solo-consultazione
Archived
2026-11-06T09:24:50.566Z
SHA-256 of the archived text
65d7a29fb740f665ced2afbe606ce12fba3c548c1646cff239771ffb313d93e2
Stable URL of this page
https://metraipolis.com/documento/dc_8188accc968d

How to cite

Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial — Europe PMC PMID:41572426 — Europe PMC (en), https://europepmc.org/article/MED/41572426 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8188accc968d (Metraipolis archive dc_8188accc968d, sha256 65d7a29fb740f665ced2afbe606ce12fba3c548c1646cff239771ffb313d93e2)
BibTeX
@misc{dc8188accc968d,
  title = {Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial — Europe PMC PMID:41572426},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41572426},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8188accc968d; sha256 65d7a29fb740f665ced2afbe606ce12fba3c548c1646cff239771ffb313d93e2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41572426. Agents can read the archived copy with the MCP tool read_document.